Inventor profile of:

Mark Winderlich

City:

Munich

Country:

Germany

Published Applications:

20

Last publication date:

2025-06-19

Top Assignees for applications by Mark Winderlich

The entities that hold a legal rights for patent applications filed by inventor Winderlich Mark:

Recent patent applications by Winderlich Mark

Mark Winderlich from Munich, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-06-19
US20250195646A1
Human necessities

COMBINATIONS AND USES THEREOF

#2 | 2025-06-12
US20250186460A1
Human necessities

TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT

#3 | 2024-12-26
US20240424012A1
Human necessities

COMBINATIONS AND USES THEREOF

#4 | 2024-11-07
US20240366756A1
Human necessities

COMBINATIONS AND USES THEREOF

#5 | 2024-01-11
US20240009196A1
Human necessities

COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF

#6 | 2022-09-08
US20220283166A1
Physics

METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS

#7 | 2022-03-24
US20220088197A1
Human necessities

Combinations and uses thereof

#8 | 2021-09-23
US20210292410A1
Chemistry; metallurgy

TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT

#9 | 2020-11-12
US20200353077A1
Human necessities

COMBINATIONS AND USES THEREOF

#10 | 2020-11-12
US20200352975A1
Human necessities

COMBINATIONS AND USES THEREOF

#11 | 2020-07-02
US20200206228A1
Human necessities

COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF

#12 | 2019-06-27
US20190195879A1
Physics

METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS

#13 | 2018-08-16
US20180228893A1
Human necessities

Combinations and uses thereof

#14 | 2018-06-07
US20180153892A1
Human necessities

Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof

#15 | 2018-01-25
US20180022823A1
Chemistry; metallurgy

Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomide

#16 | 2016-08-04
US20160222127A1
Chemistry; metallurgy

Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomib

#17 | 2015-01-15
US20150017160A1
Human necessities

Combinations and uses thereof

#18 | 2014-09-11
US20140255427A1
Human necessities

COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD

#19 | 2014-08-14
US20140227277A1
Human necessities

Combination therapy with an anti-CD19 antibody and a purine analog

#20 | 2013-11-14
US20130302318A1
Human necessities

Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL

InventorID:

528284 ⎘